487 related articles for article (PubMed ID: 30323045)
1. Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in
Poirel L; Ortiz De La Rosa JM; Kieffer N; Dubois V; Jayol A; Nordmann P
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323045
[TBL] [Abstract][Full Text] [Related]
2. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
[TBL] [Abstract][Full Text] [Related]
3. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
Ortiz de la Rosa JM; Nordmann P; Poirel L
J Antimicrob Chemother; 2019 Jul; 74(7):1934-1939. PubMed ID: 31225611
[TBL] [Abstract][Full Text] [Related]
4. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
[TBL] [Abstract][Full Text] [Related]
5. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
Gill CM; Aktaþ E; Alfouzan W; Bourassa L; Brink A; Burnham CD; Canton R; Carmeli Y; Falcone M; Kiffer C; Marchese A; Martinez O; Pournaras S; Satlin M; Seifert H; Thabit AK; Thomson KS; Villegas MV; Nicolau DP;
Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2533-2541. PubMed ID: 34291323
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the
Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
[No Abstract] [Full Text] [Related]
7. Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
Arca-Suárez J; Fraile-Ribot P; Vázquez-Ucha JC; Cabot G; Martínez-Guitián M; Lence E; González-Bello C; Beceiro A; Rodríguez-Iglesias M; Galán-Sánchez F; Bou G; Oliver A
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383659
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
Sid Ahmed MA; Abdel Hadi H; Hassan AAI; Abu Jarir S; Al-Maslamani MA; Eltai NO; Dousa KM; Hujer AM; Sultan AA; Soderquist B; Bonomo RA; Ibrahim EB; Jass J; Omrani AS
J Antimicrob Chemother; 2019 Dec; 74(12):3497-3504. PubMed ID: 31504587
[TBL] [Abstract][Full Text] [Related]
9. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
Ruedas-López A; Alonso-García I; Lasarte-Monterrubio C; Guijarro-Sánchez P; Gato E; Vázquez-Ucha JC; Vallejo JA; Fraile-Ribot PA; Fernández-Pérez B; Velasco D; Gutiérrez-Urbón JM; Oviaño M; Beceiro A; González-Bello C; Oliver A; Arca-Suárez J; Bou G
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0206721. PubMed ID: 34930034
[TBL] [Abstract][Full Text] [Related]
10. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
[No Abstract] [Full Text] [Related]
11. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
O'Neall D; Juhász E; Tóth Á; Urbán E; Szabó J; Melegh S; Katona K; Kristóf K
Acta Microbiol Immunol Hung; 2020 Mar; 67(1):61-65. PubMed ID: 32208923
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
Weber C; Schultze T; Göttig S; Kessel J; Schröder A; Tietgen M; Besier S; Burbach T; Häussler S; Wichelhaus TA; Hack D; Kempf VAJ; Hogardt M
Microbiol Spectr; 2022 Oct; 10(5):e0169722. PubMed ID: 36190424
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
Gill CM; Nicolau DP;
J Antimicrob Chemother; 2022 Dec; 78(1):252-256. PubMed ID: 36411249
[TBL] [Abstract][Full Text] [Related]
14. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
Wi YM; Greenwood-Quaintance KE; Schuetz AN; Ko KS; Peck KR; Song JH; Patel R
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29133568
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
Arca-Suárez J; Lasarte-Monterrubio C; Rodiño-Janeiro BK; Cabot G; Vázquez-Ucha JC; Rodríguez-Iglesias M; Galán-Sánchez F; Beceiro A; González-Bello C; Oliver A; Bou G
J Antimicrob Chemother; 2021 Jan; 76(1):91-100. PubMed ID: 33083833
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.
Sader HS; Flamm RK; Carvalhaes CG; Castanheira M
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224535
[No Abstract] [Full Text] [Related]
17. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
18. Integrated Genome-Wide Analysis of an Isogenic Pair of
Huang W; Hamouche JE; Wang G; Smith M; Yin C; Dhand A; Dimitrova N; Fallon JT
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033143
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021.
Lee YL; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2023 Aug; 62(2):106867. PubMed ID: 37244423
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
Mirza HC; Hortaç E; Koçak AA; Demirkaya MH; Yayla B; Güçlü AÜ; Başustaoğlu A
J Glob Antimicrob Resist; 2020 Mar; 20():334-338. PubMed ID: 31568882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
